Multicenter, Open-label, Randomised, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a Double-blind, Randomised, Parallel-group, Placebo-controlled 4 Weeks Extension Phase in Paediatric Patients With Sickle Cell Disease
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Ticagrelor (Primary)
- Indications Sickle cell anaemia
- Focus Pharmacokinetics
- Acronyms HESTIA 1
- Sponsors AstraZeneca
- 10 Mar 2017 Status changed from active, no longer recruiting to completed.
- 12 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2016 Planned End Date changed from 1 Apr 2017 to 1 Feb 2017.